Contact

News

Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimer’s Drug Discovery

CONTACT: Tara Stultz, M: 440-225-9595, tara.stultz@ritzcommunications.com Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimer's Drug Discovery Study suggests novel insulin sensitizer may prevent cognitive decline in…
continue reading